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Abstract
Introduction: Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints and
the presence of autoantibodies directed against proteins containing the non-standard arginine-derived amino acid
citrulline. The protein fibrinogen, which has an essential role in blood clotting, is one of the most prominent
citrullinated autoantigens in RA, particularly because it can be found in the inflamed tissue of affected joints. Here,
we set out to analyze the presence of citrullinated endogenous peptides in the synovial fluid of RA and arthritic
control patients.
Methods: Endogenous peptides were isolated from the synovial fluid of RA patients and controls by filtration and
solid phase extraction. The peptides were identified and quantified using high-resolution liquid chromatography-
mass spectrometry.
Results: Our data reveal that the synovial fluid of RA patients contains soluble endogenous peptides, derived from
fibrinogen, containing significant amounts of citrulline residues and, in some cases, also phosphorylated serine.
Several citrullinated peptides are found to be more abundantly present in the synovial fluid of RA patients
compared to patients suffering from other inflammatory diseases affecting the joints.
Conclusions: The increased presence of citrullinated peptides in RA patients points toward a possible specific role
of these peptides in the immune response at the basis of the recognition of citrullinated peptides and proteins by
RA patient autoantibodies.
Introduction
Rheumatoid arthritis (RA) is one of the most common
autoimmune diseases, for which many autoantigens have
been identified over the last decades. The most remarkable
but yet most common targets of autoantibodies in RA are
proteins containing the amino acid citrulline. This group
of proteins includes, among others, histones and fibrin
(ogen) [1-3]. Autoantibodies against citrullinated proteins
(ACPA) are almost exclusively present in RA and can be
present years before disease onset [4]. Detection of ACPA
or other autoantibodies is a common part of the clinical
diagnosis of RA. ACPA are often detected using the so-
called cyclic citrullinated peptide, or CCP test [5].
Fibrinogen is a heteromultimeric protein consisting of
two copies each of three different peptide chains (alpha,
beta and gamma) [6]. It plays an essential role in the clot-
ting cascade, where it is proteolytically cleaved by throm-
bin to form the clotting protein fibrin [7]. Citrullinated
forms of the alpha and beta chains of fibrinogen are
known to be present in the serum and synovial fluid (SF)
of RA patients and can be targets for ACPA [1,8]. The role
of citrullinated proteins and antibodies recognizing these
proteins in the pathophysiology of RA is not fully under-
stood, but specific human leukocyte antigen (HLA) alleles
(HLA-DR4 and HLA-DR1, HLA-DR10 and HLA-DR14)
have been linked to a predisposition to develop RA and
the associated major histocompatibility complex (MHC)
* Correspondence: r.raijmakers@uu.nl; R.Raijmakers@uu.nl
1Biomolecular Mass Spectrometry and Proteomics Group, Bijvoet Center for
Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences,
Utrecht University and Netherlands Proteomics Centre, Padualaan 8, Utrecht,
3584 CH, The Netherlands
Full list of author information is available at the end of the article
Raijmakers et al. Arthritis Research & Therapy 2012, 14:R114
http://arthritis-research.com/content/14/3/R114
© 2012 Raijmakers et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
molecules were found to show increased ability to present
peptides containing a citrulline residue [9,10]. Importantly,
HLA-DR4 transgenic mice are susceptible to develop
arthritis when immunized with citrullinated fibrinogen [8].
Recently, Ho and others found that mice that were immu-
nized with citrullinated fibrinogen developed arthritis and
fibrinogen-reactive T cells which produce the proinflam-
matory cytokines IL-6, IL-17, TNF-alpha, and IFN-gamma
and that these mice possess rheumatoid factor (RF), circu-
lating immune complexes and anti-CCP antibodies, all of
which are characteristics of human RA [11]. Inhibition of
the enzymes responsible for the generation of citrulline
residues in proteins, the peptidylarginine deiminases
(PADs), has been shown to reduce symptoms in mouse
models of RA [12]. Immune complexes consisting of
ACPA and citrullinated fibrinogen can also be found in a
large part of the ACPA-positive RA patients [13] and are
known to induce macrophage secretion of TNF-alpha, an
important mediator of inflammation in RA [14].
Although the presence of citrullinated fibrinogen pro-
tein has attracted the most attention lately, it is known
that fibrinogen-derived peptides can be present in the
synovial fluid of inflamed joints [15] and that (citrulli-
nated) peptides can be potent activators of cells of the
immune system [8,16]. Here, we analyzed the synovial
fluid obtained from 11 RA patients and 10 patients with
related inflammatory diseases of the joint for the pre-
sence of endogenous soluble citrullinated peptides by
liquid chromatography-tandem mass spectrometry (LC-
MS/MS). We found that fibrinogen-derived citrullinated
peptides were significantly more abundant in the fluid of
the RA patients compared to the control patients, while
their noncitrullinated counterparts were present at simi-
lar levels.
Materials and methods
Synovial fluid samples
Synovial fluid samples were obtained from 11 RA
patients and 10 patients with other inflammatory dis-
eases (four with psoriatic arthritis, two with ankylosing
spondylitis, two with gout, one with osteoarthritis and
one with ochronosis). Synovial fluid was obtained by
joint punctures (arthrocentesis), using needles with a
diameter from 1.6 to 2.2 mm. A sample was immedi-
ately centrifuged at 2,500 × g for 10 minutes at 4°C.
Supernatant and pellet were separately stored at -80°C.
All procedures were performed within two hours. All
samples were collected for diagnostic purposes and all
patients gave informed consent that the samples could
also be used anonymously for research purposes, in
accordance with the ethical guidelines as established by
the ethics committee of the University Medical Centre
Ljubljana (Slovenia).
Isolation of peptides from synovial fluid
Peptides were isolated from synovial fluid based on the
protocol recently described by Kamphorst et al. [15].
First, intact proteins were removed from the synovial
fluid by ultracentrifugation. Spin filter columns with a
10 kD cutoff were first washed with 100 μl ethanol by
centrifugation for 10 minutes at 11,000 × g at 4°C and
then with 100 μl 50 mM NH4HCO3 pH 7, also for 10
minutes at 11,000 × g at 4°C. Next, 50 μl of synovial fluid
was mixed with 235 ul of 50 mM NH4HCO3 pH 7 and
15 μl DMSO and was passed through the spin filter by
centrifugation for 60 minutes at 11,000 × g at 4°C. The
spin filter was then washed again with 100 μl 50 mM
NH4HCO3 pH 7 for 10 minutes at 11,000 × g at 4°C and
the filtrates of the last two steps were combined and acid-
ified with 5 μL formic acid (FA). Next, Sep-Pak C18
(Waters Corp., Milford, MA, USA) disposable cartridges
with a capacity of 50 mg were activated with 1 ml aceto-
nitrile (ACN) and conditioned with 1 ml 2.5% ACN/1%
FA. After passing the filtrates over the cartridges, they
were washed with 1 ml 2.5% ACN/1% FA. Finally, pep-
tides were eluted with 150 μL 80% ACN/1% FA and
dried by vacuum centrifugation. For mass spectrometry
(MS) analysis, dried peptide samples were reconstituted
in 50 μl of 5% FA. Five μl of each sample was spiked with
1 μl of internal standard, containing three standard pep-
tides with mass-to-charge ratio (m/z) of 556.28, 477.78,
and 497.60.
Identification and quantitation of endogenous peptides
by LC-MS/MS
Isolated synovial fluid peptides were analyzed by nanos-
cale liquid C18 chromatography using an Agilent 1100
series LC system coupled to an LTQ-FT-ICR mass spec-
trometer (Thermo Fisher Scientific Inc., Waltham, MA,
USA). The mass spectrometer was operated in the data-
dependent mode to automatically switch between MS
and MS/MS acquisition and the five most intense ions
were fragmented in the linear ion trap using collisionally
induced dissociation.
Obtained MS/MS spectra were analyzed by database
searching against all human proteins in the SwissProt
database using the Mascot software platform version
2.1.0 (Matrix Science Ltd., London, UK). The search cri-
teria included methionine oxidation, arginine citrullina-
tion and asparagine and glutamine deamidation as
variable modifications. The peptide tolerance was set to
5 ppm and the MS/MS tolerance to 0.6 Da. All searches
were done without enzyme restrictions and peptides
were, unless described differently, identified with a mini-
mum Mascot score of 35. For spectral counting, peptide
spectrum matches with a Mascot score of at least 20
were included. Technical details of the LC-MS/MS
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analysis and database searching can be found in Addi-
tional file 1.
Results
To assess the presence of citrullinated endogenous pep-
tides in the synovial fluid of RA patients, synovial fluid
and serum was collected from 11 RA patients and 10
patients with other inflammatory diseases of the joint. The
ACPA (anti-citrullinated protein antibody) status of all RA
patients was assessed by ELISA using the CCP2 test and is
given in Additional file 1, Table S1. Endogenous peptides
with a size smaller than 10 kDa were isolated from the
synovial fluid by ultrafiltration and solid phase extraction.
Identification of endogenous citrullinated peptides
The synovial fluid-derived peptides were analyzed by LC-
MS/MS on a high-resolution LTQ-FT-ICR mass spectro-
meter and the resulting spectra were searched against all
human proteins in the SwissProt database, allowing for
citrullination, deamidation and oxidation as variable modi-
fications. Because citrullination leads to an additional mass
of nominally one Dalton compared to regular arginine
residues, such searches are prone to false positives stem-
ming from the misidentification of 13C isotopes or modifi-
cations that lead to similar nominal mass increases (for
example, deamidation of asparagines or glutamine). Such
false, randomly matched, identifications are expected to
have lower identification scores, because the identification
score itself is calculated using the probability that an
observed match between experimental data in the MS/MS
spectra and a database sequence is random. We plotted
the average relative number of peptides containing citrul-
line residues at various cutoff scores for patient and con-
trol samples (Figure 1). This showed that, at lower scores,
the percentage of identified citrullinated peptides was
almost 25% in patient samples and that this value dropped
when higher cutoff scores were used leveling off at
approximately 10% at cutoff scores of 35 and higher.
Therefore, we chose to include only peptides identified
with a score of at least 35 for further analysis. This analysis
also showed that, irrespective of score cutoff, the average
number of citrullinated peptides identified in RA patients
was higher than in control patients. Because we were
mainly interested in citrullinated peptides elevated in the
RA patients, we generated a first list of candidate peptides
based on their spectral counts in the two patient groups.
We selected all peptides that were identified in at least
two more RA patients than control patients and had an
overall spectral count which was 2.5 times higher in the
RA patients compared to controls. This resulted in a list
of 17 citrullinated peptides, 15 of which we identified as
being derived from the alpha chain of fibrinogen (Table 1).
This is similar to previous reports [15] and is not unex-
pected, as (citrullinated) fibrinogen alpha is known to be
highly abundant in the synovial fluid proteome [3] and,
unlike many other proteins, undergoes efficient proteolysis
as part of the blood clotting cascade. While other proteins
might be even more abundantly present in the synovial
fluid (for example, albumin or antibodies) [17], these
would not be detected in this study, because they are not
as commonly proteolytically processed as fibrinogen.
Figure 2A shows the LC-MS chromatogram of the syno-
vial fluid of patient S13, with all major peaks correspond-
ing to fibrinogen-derived peptides indicated to illustrate
that these peptides dominate the chromatogram.
Given the difficulties with the reliable identification of
citrullinated peptides described above, further analyses
were performed to unambiguously confirm the citrullina-
tion of each of these 17 peptides. Misidentification of 13C
isotopes was prevented by choosing a stringent precursor
tolerance (5 ppm) for the initial searches, taking into
account that 13C leads to a larger mass difference (1.0036
Da) than citrullination (0.9802 Da). Deamidation, on the
other hand, cannot be discriminated from citrullination
based upon mass alone. However, deamidation does not
change the number of charged residues in the peptide
(under the acidic conditions used for LC-MS), whereas
the conversion of arginine to citrulline neutralizes a posi-
tive charge. Therefore, we anticipated citrullination to
have a pronounced effect on ionization and fragmenta-
tion of the peptide, and on the elution time of the peptide
in the reversed phase separation preceding our MS analy-
sis. We analyzed the retention times of all peptides in
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Figure 1 Identified citrullinated peptides at various
identification scores. Graph showing the average percentage of all
identified peptides that contain at least one citrulline residue at
varying identification threshold scores in the synovial fluid of
rheumatoid arthritis (RA) patients (black line) and control patients
(dashed grey line). Bars indicate the median absolute deviations and
asterisks indicate the scores at which a statistically significant
difference (P < 0.05) was observed, as determined by a Mann-
Whitney test.
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Table 1 and compared them with the corresponding non-
citrullinated peptides. This revealed that, on average,
citrullinated peptides eluted five minutes later from the
C18 column than their arginine-containing counterparts
(Figure 2B and Additional file 1, Table S2), in agreement
with their increased hydrophobicity. We also analyzed
the precursor mass spectra and fragmentation spectra for
all of these peptides and found that citrullination caused
the dominant precursor charge state to be lower for pep-
tides with a charge of three and higher (Figure 3 and
Additional file 1, Table S2), whereas deamidation had no
such effect (data not shown). Also the MS/MS spectra
changed upon citrullination, as anticipated, with more
prominent b-ions showing up when the converted argi-
nine was on the C-terminal part of the peptide and
increased levels of y-ions when it was located more N-
terminally (Figure 3).
Quantification of endogenous citrullinated peptides
Having robustly established the citrullinated identity of
these peptides, we set out to analyze their abundance in
the synovial fluid. From the sequence of the peptides, it
was apparent that mostly two regions of fibrinogen were
identified with multiple peptides, with different termini,
probably due to endogenous proteolytic activity. These
two regions span amino acids 20-35 (sequence
ADSGEGDFLAEGGGVR) and 414-433 (sequence
EEVSGNVSPGTRREYHTEKL) of the fibrinogen alpha
chain. The first sequence corresponds to the so-called
fibrinopeptide A, a signal peptide generated from the N-
terminus of fibrinogen alpha during blood clotting.
Because of their prominent presence, we decided to focus
on these regions, and to include other peptides covering
these sequences in further analyses. We determined the
relative abundance of all selected peptides in all samples
by calculating the area of their extracted ion chromato-
grams (XIC) in the LC-MS analyses (as is shown for pep-
tide DSGEGDFLAEGGGVR in Figure 2B), normalized
using spiked (citrullinated) synthetic peptides. Figure 4A
shows a heat map displaying the abundance of each of
these citrullinated peptides for fibrinogen region 20-35 in
the synovial fluid samples, suggesting that some of them
are more often present in high amounts in RA patients
compared to controls. This effect can be attributed both
to an increase in the total amount of peptide present and
to an increased level of citrullination. Therefore, we also
calculated the extract ion chromatogram areas for all cor-
responding noncitrullinated peptides (Figure 4B). This
revealed that the increased levels observed for the citrul-
linated peptides were not seen for their noncitrullinated
counterparts, suggesting an increased level of citrullina-
tion. A similar analysis of region 414-433 is shown in
Additional file 1, Figure S1 and showed a higher abun-
dance of both the citrullinated and the noncitrullinated
peptides in the RA patients.
To visualize the changed levels of citrullination for the
peptides covering amino acids 20-35 of fibrinogen alpha,
we also calculated the average relative amount of
selected citrullinated peptides versus their noncitrulli-
nated counterpart by calculating the ratio between the
Table 1 List of citrullinated peptides identified more often in rheumatoid arthritis patients compared to control
patients.
Sequence Protein Accession Score
DSGEGDFLAEGGGVcR Fibrinogen a chain FIBA_HUMAN 87.8
SGEGDFLAEGGGVcR Fibrinogen a chain FIBA_HUMAN 67.8
EGDFLAEGGGVcR Fibrinogen a chain FIBA_HUMAN 73.2
FLAEGGGVcR Fibrinogen a chain FIBA_HUMAN 50.9
EEVSGNVSPGTRcR Fibrinogen a chain FIBA_HUMAN 51.5
EEVSGNVSPGTRcRE Fibrinogen a chain FIBA_HUMAN 69.8
EEVSGNVSPGTcRREY Fibrinogen a chain FIBA_HUMAN 60.0
EEVSGNVSPGTRcREY Fibrinogen a chain FIBA_HUMAN 48.8
ELEcRPGGNEITRGGSTSY Fibrinogen a chain FIBA_HUMAN 50.1
NcRGDSTFESKSY Fibrinogen a chain FIBA_HUMAN 69.0
DEAGSEADHEGTHSTKcRGHA Fibrinogen a chain FIBA_HUMAN 40.8
GSTGNcRNPGSSGTGGTATWKPGSSGP Fibrinogen a chain FIBA_HUMAN 59.1
SETEScRGSESGIFTNTK Fibrinogen a chain FIBA_HUMAN 49.6
SSSYSKQFTSSTSYNcRGDSTF Fibrinogen a chain FIBA_HUMAN 41.9
TcRGGSTSYGTGSETESPRNPS Fibrinogen a chain FIBA_HUMAN 52.0
TSEASSSSSSSSSSSRScRScRSL Peroxisome proliferator-activated receptor gamma coactivator-related protein 1 PPRC1_HUM 68.1
GLADNTNDLEKcRcR Plasma membrane calcium-transporting ATPase 3 AT2B3_HUMAN 40.5
Note: cR indicates the position of a citrulline residue.
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observed areas for these peptides. This revealed that the
noncitrullinated peptides are detected in roughly 100-
fold higher amounts (shown in Figure 5 by the approxi-
mate average ratio of 0.01), but this does not reflect
actual abundances because the arginine-containing pep-
tides will be detected much more efficiently due to their
higher basicity and thus ionization efficiency [18]. Still,
the data can be interpreted relative to each other and
although the difference between individual patients is
large, it is clear that a significant increase of the citrulli-
nated variants of the peptide was observed in the RA
patients (Figure 5). For both combinations of corre-
sponding citrullinated and noncitrullinated peptide
sequences shown in Figure 5, a t test on the log-trans-
formed areas revealed significant differences between
RA patients and control patients with P values of < 0.05.
In addition, for both sets also the categorical Fisher’s
exact test (using cutoff 0.01) confirmed the significant
differences with P < 0.05. The ratios for all peptides cor-
responding to amino acids 20-35 of fibrinogen alpha are
shown in Additional file 1, Figure S2.
Synovial fluid contains multiply modified fibrinopeptide A
Interestingly, fibrinopeptide A also contains a known
phosphorylation site on fibrinogen alpha (S22) [19],
which is most likely generated by a member of the
casein kinase II (CK2) family [20]. To determine if the
presence or absence of phosphorylation was in any way
linked to the citrullination of R35, we extended our
database search to include this possibility and were able
to identify two peptides (with sequences ADpSGEGD-
FLAEGGGVcR and DpSGEGDFLAEGGGVcR) contain-
ing both a phosphorylated S22 and a citrullinated R35
in a number of the patients (Additional file 1, Figure
S3A). We then also determined the XIC areas of these
peptides in all patients, showing that the peptides con-
taining both modifications showed a similar behavior to
the peptides containing only the citrullination site (for
example, more present in RA patients), whereas peptides
containing only the phosphorylation site were equally
abundant in all patients (Additional file 1, Figure S3B).
A final fibrinopeptide A-derived phosphopeptide con-
taining a citrulline residue with sequence pSGEGD-
FLAEGGGVcR was identified with low identification
scores in some of the samples, but was found to be pre-
sent in only very low amounts and was, therefore, not
included in this analysis (data not shown).
Discussion
Many citrullinated proteins have been identified in the
inflamed joints of RA patients and a number of these
have been shown react in vitro with ACPA. A promi-
nent candidate to be the main target for ACPA is fibrin
(ogen), which is known to be present in large amounts
in inflamed joints and which is known to be present in
a citrullinated form in the synovial fluid of RA patients
[3,21]. ACPA can indeed bind to citrullinated fibrinogen,
in particular the alpha chain. Recently, it was shown that
in inflamed joints also significant amounts of peptides
can be found that are derived from fibrinogen, due to
endogenous proteolytic activity [15]. Here, we showed
that citrullinated versions of these peptides can be
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Figure 2 Chromatography of synovial fluid and fibrinogen-
derived peptides. Panel A contains a base peak chromatogram of
the LC-MS/MS analysis of the peptides in the synovial fluid of
rheumatoid arthritis (RA) patient S13, showing the complexity of the
sample. All base peaks derived from the alpha chain of fibrinogen
are indicated with ‘F’, with citrullinated and phosphorylated
peptides indicated with ‘cF’ and ‘pF’, respectively. Panel B shows the
extracted ion chromatograms (XIC) of peptide DSGEGDFLAEGGGVR
(mass-to-charge ratio (m/z) 733.33), which elutes at a retention time
(RT) of 53.18 minutes and the citrullinated version of the same
peptide (m/z 733.83), eluting at 61.08 minutes. Note that in the
bottom chromatogram also a peak is visible at the elution time of
the noncitrullinated peptide, corresponding to the 13C isotopic peak
of that peptide, which has a mass very close to the citrullinated
peptide and is, therefore, also extracted by the algorithm. The
relative areas of the two extracted chromatograms are indicated at
the y-axis of the XICs. LC-MS/MS, liquid chromatography-tandem
mass spectrometry.
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found in the synovial fluid of inflamed joints. While
some of these citrullinated peptides were equally abun-
dant in the RA patients and the control group with
patients suffering from other inflammatory joint dis-
eases, others appeared to be more abundant in RA
patients (Table 1). Consistent with that observation,
PAD activity in joints is known to be elevated in such
other inflammatory diseases as well. The higher level of
some of the peptides in RA patients suggests that a dif-
ferent immune response toward these peptides might
occur in RA patients, leading to, for example, prolonged
retention of these peptides, which, in turn, could contri-
bute to increased immune system activation. Although
there was significant diversity in the levels of
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Figure 3 Identification of citrullinated peptides. MS1 (left) and MS/MS (right) spectra of two different fibrinogen-derived peptides
(DSGEGDFLAEGGGVR in panel A and NRGDSTFESKSY in panel B) from synovial fluid samples. In the MS1 spectra, the peak(s) corresponding to
the respective peptide are marked with their mass-to-charge ratio (m/z) and charge state, the peak of which the MS/MS spectrum is shown and
is marked with the red m/z value. In the corresponding MS/MS spectra, y-ions are marked in blue, b-ions are marked in red and all other
annotated ions are marked in green. Please note that parent ions are not present in the MS/MS spectra generated with the instrumentation and
settings used. MS, mass spectrometry; MS/MS, tandem mass spectrometry.
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citrullinated peptides in the control group, with espe-
cially patient S2 (ankylosing spondylitis) showing very
high levels, no obvious relation with their diagnosed dis-
ease was apparent (Additional file 1, Table S1). This
diversity among the patients in the control group con-
firms that the citrullinated peptides arose from inflam-
matory events that can also occur in diseases other than
RA, which is not unexpected as many rheumatic dis-
eases show overlap in the symptoms observed. An ideal
control material would be synovial fluid from healthy
individuals, but for obvious reasons this material is less
readily available, not only due to ethical issues, but also
because the amount of synovial fluid in noninflamed
joints is much smaller.
The citrullinated peptides we found to be most abun-
dantly present in RA patients covered mainly two dis-
tinct regions in the alpha chain of fibrinogen, amino
acids 20-35 and 414-433. These regions have been
shown to be susceptible to citrullination in the past and
it was shown that the arginine residues in these
sequences (R35, R425 and R426) can be citrullinated by
both the PAD2 as well as the PAD4 enzymes [22], both
known to be present in inflammatory cells in the syno-
vium [23]. Together, these PAD enzymes are known to
be able to citrullinate two-thirds of all arginine residues
in fibrinogen [22], but little is known about which
citrullinated residues contribute most to eliciting the
anti-citrullinated protein immune response. The fact
that specific citrullinated fibrinogen-derived peptides
reside in the synovial fluid makes them prime candi-
dates for having a role in the immune response against
citrullinated epitopes.
The fibrinogen region between amino acids 414-433 is
known to be autoantigenic in RA patients [6,22], but for
the citrullinated fibrinopeptide A (amino acids 20-35)
no data on autoantigenicity is available, most likely
because it is not part of the mature fibrinogen protein
that has been used in such studies most frequently.
Interestingly, the fact that fibrinopeptide A, after clea-
vage from the fibrinogen precursor, contains a C-term-
inal arginine residue makes it an excellent substrate for
PAD enzymes, which are able to efficiently convert such
residues to citrulline (data not shown).
Both sequence elements were represented by a variety
of peptides, differing in either their N- or C-terminal
sequence (Figures 4 and S1), most likely due to in vivo
proteolytic activities. While it is difficult to predict the
enzyme responsible for their generation, proteases abun-
dantly present in inflammatory cells, such as matrix
metalloproteinases, elastases or caspases are likely
involved. The two cleavage sites generating the full
amino acids 20-35 fragment, however, are obvious, as
this corresponds exactly to the borders of fibrinopeptide
A, which is released from the A-alpha chain by cleavage
at the N-terminal side of amino acid 20 by the signal
peptidase and at the C-terminal side of amino acid 35
A
B
Average intensity
S2 S3 S44 S33 S51 S32 S37 S4 S20 S40 S13 S28 S42 S34 S25 S53 S45 S49 S22 S29 S47
Disease Controls RA paƟents
Average intensity
100%
75%
50%
25%
0%
100%
75%
50%
25%
0%
DSGEGDFLAEGGGVcR *
SGEGDFLAEGGGVcR *
GEGDFLAEGGGVcR *
EGDFLAEGGGVcR *
GDFLAEGGGVcR *
DFLAEGGGVcR *
FLAEGGGVcR *
GDFLAEGGGVR *
DSGEGDFLAEGGGVR *
SGEGDFLAEGGGVR *
GEGDFLAEGGGVR *
EGDFLAEGGGVR *
DFLAEGGGVR *
FLAEGGGVR *
citrulline
arginine
S51 S3 S40 S44 S2 S33 S20 S4 S32 S37 S25 S13 S34 S28 S29 S47 S42 S45 S22 S53 S49
Disease Controls RA paƟents
Figure 4 Abundance of fibrinopeptide A-derived peptides in rheumatoid arthritis (RA) patients and controls. Heat map displaying the
relative abundance as determined from the extracted ion chromatograms, (XIC) of citrullinated peptides (panel A) and their noncitrullinated
counterparts (panel B) in RA patients and control patients. Because the abundance of different peptides cannot be directly compared due to
their different behavior in the mass spectrometer, the colour coding is applied per peptide sequence, with the patient containing the highest
amount of each particular peptide coloured in red, the lowest coloured in green and the other patients coloured according to the colour scale
shown on the right of the panel. White asterisks indicate in which patient the highest abundance of a specific peptide was observed. For the RA
patients, the code of CCP2+ patients is shown in yellow and of CCP2- patients in red. Patients are sorted according to the average abundance
of all listed peptides, shown at the bottom of each panel. CCP, cyclic citrullinated peptide.
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by thrombin [7,24] The latter cleavage is one of the first
steps of the clotting cascade and therefore the presence
of (derivatives of) fibrinopeptide A is not very surprising,
although its presence in a citrullinated fashion has not
been reported before. Because thrombin cleavage at that
position is dependent on the presence of an arginine
residue, the citrullination of the C-terminal arginine of
fibrinopeptide A has most likely occurred after thrombin
cleavage. Citrullination of R35 in the uncleaved fibrino-
gen protein would inhibit thrombin cleavage and might,
therefore, have implications on the efficiency of clotting
in inflamed joints [25]. The cleavage generating the N-
terminus of the amino acids 414-433 fragment is most
likely mediated by cathepsin D, which can cleave fibri-
nogen at that position in the process of clearing fibrin
cloths [26].
Fibrinogen is certainly not the only citrullinated anti-
gen present in synovial fluid as, for example, citrulli-
nated fibronectin and vimentin have also been found
[21]. However, the presence of high levels of endogen-
ous citrullinated peptides derived from the protein is
quite unique to fibrinogen, and could potentially provide
a direct link between with the generation of an immune
response targeting citrullinated epitopes. From a diag-
nostic point of view, such peptides might be very inter-
esting to discriminate RA from closely related
inflammatory diseases that also affect the joints. This
could be achieved either by employing targeted mass
spectrometric techniques or by the development of
alternative, for example, antibody-based methods that
would allow the specific detection of these citrullinated
peptides in synovial fluid samples.
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Figure 5 Relative abundance of citrullinated peptides and their noncitrullinated counterparts. Bar graphs showing the ratio between the
abundance of a specific citrullinated peptide versus its noncitrullinated variant in rheumatoid arthritis (RA) patients (black bars) and control
patients (gray bars) on a base 10 logarithmic scale. Panel A shows the ratios for peptide GDFLAEGGGVR and panel B for peptide
SGEGDFLAEGGGVR. When no signal for the peptide was detected, a value equivalent to the background signal was assigned for this calculation.
If both the signal of the citrullinated and the noncitrullinated peptide were missing, the ratio is shown as not determined (n.d.). Patients are
sorted per group according to the observed ratios.
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Conclusions
We have shown the presence of increased amounts of
specific endogenous citrullinated peptides, derived from
fibrinogen, in the synovial fluid of RA patients. Citrulli-
nated fibrinopeptide A was found to be present more
abundantly in RA patients compared to control patients
and compared to the not citrullinated fibrinopeptide.
This elevated presence could indicate a role for such
endogenously generated, citrullinated peptides in the
development of the anti-citrullinated protein antibody
(ACPA) immune response that is often seen in RA
patients.
Additional material
Additional file 1: A PDF file containing all supplementary methods,
tables and figures as referred to in the main text. The additional file
contains supplementary methods on ‘LC-MS/MS’ and ‘Identification and
quantitation of endogenous peptides’, a link to all identification results as
deposited in the ProteomeCommons.org Tranche, supplementary tables
S1 (’List of patients included and CCP status of RA patients’) and S2 (’LC-
MS characteristics of identified citrullinated peptides and their
noncitrullinated counterparts’) and supplementary figures S1 (’Abundance
of fibrinogen amino acids 414-433-derived peptides in RA patients and
controls’), S2 (’Relative abundance of citrullinated peptides and their
noncitrullinated counterparts’) and S3 (’The presence of phosphorylated
and citrullinated peptides in synovial fluid’).
Abbreviations
ACN: acetonitrile; ACPA: anti-citrullinated protein antibodies; CCP: cyclic
citrullinated peptide; ELISA: enzyme-linked immunosorbent assay; FA: formic
acid; HLA: human leukocyte antigen; IFN: interferon; IL: interleukin; kDa:
kiloDaltons; LC-MS/MS: liquid chromatography-tandem mass spectrometry;
MHC: major histocompatibility complex; MS: mass spectrometry; m/z: mass-
to-charge ratio; PAD: peptidylarginine deiminase; RA: rheumatoid arthritis; RF:
rheumatoid factor; SF: synovial fluid; TNF: tumor necrosis factor; XIC:
extracted ion chromatogram.
Acknowledgements
This work was supported in part by the Dutch Technology Foundation
(STW) and the Netherlands Proteomics Centre (NPC). We are thankful to the
clinicians of the Department of Rheumatology of the UMC Ljubljana
(Slovenia) for patient samples and clinical data.
Author details
1Biomolecular Mass Spectrometry and Proteomics Group, Bijvoet Center for
Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences,
Utrecht University and Netherlands Proteomics Centre, Padualaan 8, Utrecht,
3584 CH, The Netherlands. 2Department of Biomolecular Chemistry,
Nijmegen Center for Molecular Life Sciences, Institute for Molecules and
Materials, Radboud University Nijmegen, Geert Grooteplein 26, Nijmegen,
6525 GA, The Netherlands. 3University Medical Centre Ljubljana, Department
of Rheumatology, Immunology Laboratory, Vodnikova 62, Ljubljana, 1000,
Slovenia.
Authors’ contributions
RR, MEA and NFCV performed the proteomics experiments. RR and MEA
conducted the proteomic data analyses. BB and JJBCvB provided and
characterized samples. RR, GJMP and AJRH designed and supervised the
research. RR, JJBCvB, MEA, BB, GJMP and AJRH wrote the paper. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 January 2012 Revised: 28 March 2012
Accepted: 14 May 2012 Published: 14 May 2012
References
1. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C,
Senshu T, Serre G: The major synovial targets of the rheumatoid arthritis-
specific antifilaggrin autoantibodies are deiminated forms of the alpha-
and beta-chains of fibrin. J Immunol 2001, 166:4177-4184.
2. Matsuo K, Xiang Y, Nakamura H, Masuko K, Yudoh K, Noyori K, Nishioka K,
Saito T, Kato T: Identification of novel citrullinated autoantigens of
synovium in rheumatoid arthritis using a proteomic approach. Arthritis
Res Ther 2006, 8:R175.
3. Takizawa Y, Suzuki A, Sawada T, Ohsaka M, Inoue T, Yamada R,
Yamamoto K: Citrullinated fibrinogen detected as a soluble citrullinated
autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 2006,
65:1013-1020.
4. van Venrooij WJ, van Beers JJ, Pruijn GJ: Anti-CCP Antibody, a Marker for
the Early Detection of Rheumatoid Arthritis. Ann N Y Acad Sci 2008,
1143:268-285.
5. Pruijn GJ, Wiik A, van Venrooij WJ: The use of citrullinated peptides and
proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010,
12:203.
6. Sebbag M, Moinard N, Auger I, Clavel C, Arnaud J, Nogueira L, Roudier J,
Serre G: Epitopes of human fibrin recognized by the rheumatoid
arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol
2006, 36:2250-2263.
7. Wolberg AS: Thrombin generation and fibrin clot structure. Blood Rev
2007, 21:131-142.
8. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, Lee DM,
Hueber W, Robinson WH, Cairns E: Arthritis induced by posttranslationally
modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med
2008, 205:967-979.
9. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K,
Engstrom A, Venables PJ, Lundeberg J, Holmdahl R, Klareskog L,
Malmström V: Multiple antibody reactivities to citrullinated antigens in
sera from patients with rheumatoid arthritis: association with HLA-DRB1
alleles. Ann Rheum Dis 2009, 68:736-743.
10. Holoshitz J: The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin
Rheumatol 2010, 22:293-298.
11. Ho PP, Lee LY, Zhao X, Tomooka BH, Paniagua RT, Sharpe O, BenBarak MJ,
Chandra PE, Hueber W, Steinman L, Robinson WH: Autoimmunity against
fibrinogen mediates inflammatory arthritis in mice. J Immunol 2010,
184:379-390.
12. Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y,
Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP,
Thompson PR, Holers VM: N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-
ornithine amide, a protein arginine deiminase inhibitor, reduces the
severity of murine collagen-induced arthritis. J Immunol 2011,
186:4396-4404.
13. Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, Tomooka BH,
Gregersen PK, Robinson WH: Circulating immune complexes contain
citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 2008, 10:
R94.
14. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, Serre G:
Induction of macrophage secretion of tumor necrosis factor alpha
through Fcgamma receptor IIa engagement by rheumatoid arthritis-
specific autoantibodies to citrullinated proteins complexed with
fibrinogen. Arthritis Rheum 2008, 58:678-688.
15. Kamphorst JJ, van der Heijden R, DeGroot J, Lafeber FP, Reijmers TH, van
El B, Tjaden UR, van der Greef J, Hankemeier T: Profiling of endogenous
peptides in human synovial fluid by NanoLC-MS: method validation and
peptide identification. J Proteome Res 2007, 6:4388-4396.
16. von Delwig A, Locke J, Robinson JH, Ng WF: Response of Th17 cells to a
citrullinated arthritogenic aggrecan peptide in patients with rheumatoid
arthritis. Arthritis Rheum 2010, 62:143-149.
17. Gibson DS, Rooney ME: The human synovial fluid proteome: A key factor
in the pathology of joint disease. Proteomics Clin Appl 2007, 1:889-899.
18. Raijmakers R, Zendman AJ, Egberts WV, Vossenaar ER, Raats J, Soede-
Huijbregts C, Rutjes FP, van Veelen PA, Drijfhout JW, Pruijn GJ: Methylation
of arginine residues interferes with citrullination by peptidylarginine
deiminases in vitro. J Mol Biol 2007, 367:1118-1129.
Raijmakers et al. Arthritis Research & Therapy 2012, 14:R114
http://arthritis-research.com/content/14/3/R114
Page 9 of 10
19. Beranova-Giorgianni S, Zhao Y, Desiderio DM, Giorgianni F:
Phosphoproteomic analysis of the human pituitary. Pituitary 2006,
9:109-120.
20. Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jorgensen C, Miron IM,
Diella F, Colwill K, Taylor L, Elder K, Metalnikov P, Nguyen V, Pasculescu A,
Jin J, Park JG, Samson LD, Woodgett JR, Russell RB, Bork P, Yaffe MB,
Pawson T: Systematic discovery of in vivo phosphorylation networks. Cell
2007, 129:1415-1426.
21. Tabushi Y, Nakanishi T, Takeuchi T, Nakajima M, Ueda K, Kotani T, Makino S,
Shimizu A, Hanafusa T, Takubo T: Detection of citrullinated proteins in
synovial fluids derived from patients with rheumatoid arthritis by
proteomics-based analysis. Ann Clin Biochem 2008, 45:413-417.
22. van Beers JJ, Raijmakers R, Alexander LE, Stammen-Vogelzangs J,
Lokate AM, Heck AJ, Schasfoort RB, Pruijn GJ: Mapping of citrullinated
fibrinogen B-cell epitopes in rheumatoid arthritis by imaging surface
plasmon resonance. Arthritis Res Ther 2010, 12:R219.
23. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ: PAD, a growing
family of citrullinating enzymes: genes, features and involvement in
disease. Bioessays 2003, 25:1106-1118.
24. Rawlings ND, Barrett AJ, Bateman A: MEROPS: the peptidase database.
Nucleic Acids Res 2009, 38:D227-233.
25. Nakayama-Hamada M, Suzuki A, Furukawa H, Yamada R, Yamamoto K:
Citrullinated fibrinogen inhibits thrombin-catalysed fibrin polymerization.
J Biochem 2008, 144:393-398.
26. Simon DI, Ezratty AM, Loscalzo J: The fibrin(ogen)olytic properties of
cathepsin D. Biochemistry 1994, 33:6555-6563.
doi:10.1186/ar3840
Cite this article as: Raijmakers et al.: Elevated levels of fibrinogen-
derived endogenous citrullinated peptides in synovial fluid of
rheumatoid arthritis patients. Arthritis Research & Therapy 2012 14:R114.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Raijmakers et al. Arthritis Research & Therapy 2012, 14:R114
http://arthritis-research.com/content/14/3/R114
Page 10 of 10
